BAJAJ FINSERV DIRECT LIMITED
Latest IPO Information

Curis Lifesciences Ltd. IPO

IPO Date: Nov 7 to Nov 11 2025

Listing Date: Nov 14 2025

Objective

i.Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities;ii.Capital Expenditure towards Construction of a Storage Facility;iii.Pre-payment/Repayment of outstanding Secured Loans;iv.Product Registrations in other countries;v.Funding our Working Capital Requirements; andvi.General Corporate Purpose.

IPO Details

Face Value ₹ 10.00 Per Share
Issue Size ₹ 18.49 - 19.72 Cr
Price Band ₹ 120.00 - ₹ 128.00 Per Share
Market LOT 2000 shares
Issue Type Book building

About Company

Our business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic onloan license or contract Manufacturing and own brand marketing basis. Our business is majorly on principle to principlebasis with different marketers. As on the date of this Draft Red Herring Prospectus, we cater to more than 100 corporateclients on loan license and/or contract manufacturing basis along with 2 clients for own brand marketing globally ofRepublic of Yemen and Kenya. Our company has commenced manufacturing facility in year 2017, hence, our companyhas experience .... of more than 5 years in the current line of business of the company. as on the date of this Draft Red HerringProspectus our manufacturing facility at Curis Lifesciences Limited is installed with capacity to manufacture 138 Croretables / year, 15.75 Crore Capsules / year, 1080 Kilolitre Oral Liquid/ year, 270 Tons external preparation / year and 45Tons sterile ophthalmic ointment / year. Our promoters have a vast experience in the pharmaceutical manufacturingIndustry. Driven by the passion for building an integrated pharmaceutical company, backed by their experience, ourPromoters have been the pillars of our Company's growth and have built a strong value system for our Company. Withtheir enriching experience and progressive thinking, we aim to continue to grow in the pharmaceutical industry Read More
Address

P F-23, G I D C Sanand - I I Industrial Estate, Sanand

City

Ahmedabad

State

Gujarat

Pincode

382110

Phone

7096558558

Email

info@curisls.com

Website

www.curisls.com

About IPO

Listed At NSE
Lead Manager Finaax Capital Advisors Pvt Ltd
Promoters
Dharmesh Dashrathbhai Patel
Siddhant Jayantibhai Pawasia
Piyush Gordhanbhai Antala
Jaimik Mansukhbhai Patel

Promoter's Holding

Registrar

MUFG Intime India Pvt Ltd.

+91 810 811 8484
rnt.helpdesk@in.mpms.mufg.com
https://in.mpms.mufg.com/

Latest News

Jul
6
2026
EQUITY Posted on Jul 6th 2026

Sikozy Realtors informs about newspaper advertisement

Pursuant to Regulation 30 of SEBI (LODR) Regulation, 2015, Sikozy Realtors has informed that it has published the newspaper advertisement for Notice given in the newspaper regarding procedure for reduction of share capital of the company in the Business Standard (English) & NavShakti (Marathi) on 4th July, 2026. The necessary clippings are attached.

The above information is a part of company’s filings submitted to BSE.

Read More
Jul
6
2026
EQUITY Posted on Jul 6th 2026

Tomorrow Technologies Global Innovations informs about certificate

As required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, Tomorrow Technologies Global Innovations has informed that it enclosed certificate received from the MUFG INTIME INDIA, Registrar and Share Transfer Agent (RTA) for the QUARTER 30-06-2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
6
2026
EQUITY Posted on Jul 6th 2026

Arvaya Healthcare submits board meeting intimation

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘SEBI Listing Regulations’), Arvaya Healthcare has informed that a Meeting of the Board of Directors of the Company is scheduled to be held on Saturday, July 11, 2026 to, consider and approve: 1. To consider & approve Acquisition of Sushodha Institute of Gastroenterology and approval of Material Related Party Transactions with Bidari Kotresh Anilkumar. 2. To consider and evaluate a proposal for issuance of equity shares on a preferential basis for consideration other than cash (share swap). 3. To constitute Right Issue Committee of a Company. 4. To consider proposal to issue securities to the existing shareholders of the Company on Rights Basis, as may be permitted under applicable law, subject to such regulatory/statutory approvals as may be required. 5. To consider the approval for the postal ballot process and related actions. Further to its communication dated June 22, 2026 the trading window will be closed from July 1, 2026 which shall remain closed till 48 hours after the declaration of Unaudited Financial Results of the Company for the First Quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Read More
Jul
6
2026
EQUITY Posted on Jul 6th 2026

Genomic Valley Biotech informs about certificate

Genomic Valley Biotech has informed that it enclosed the certificate pursuant to Regulation 74 (5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended on 30th June 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
6
2026
EQUITY Posted on Jul 6th 2026

Digitide Solutions informs about grant of employee stock options

Digitide Solutions has informed that pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) and Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, the Nomination and Remuneration Committee of the Board of Directors of the Company has approved the grant of 33,75,059 options to eligible employees of the Company and its subsidiaries under the ESOS 2026. The relevant disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as Annexure -A. The above information will also be made available on the Company’s website: www.digitide.com.

The above information is a part of company’s filings submitted to BSE.

Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the issue size of Curis Lifesciences Ltd. IPO?

The issue size of Curis Lifesciences Ltd. IPO is ₹18.49 - 19.72 crore.

The Curis Lifesciences Ltd. IPO opens for subscription on 2025-11-07 and closes on 2025-11-11.

The price range of Curis Lifesciences Ltd. IPO is ₹120.00 to ₹128.00.

The lot size of Curis Lifesciences Ltd. IPO is 2000 shares.

The registrar of Curis Lifesciences Ltd. IPO is MUFG Intime India Pvt Ltd..

Curis Lifesciences Ltd. IPO will be listed on NSE .

You will typically receive a confirmation message or notification from your broker or trading platform shortly after placing your IPO order. This confirms that your application has been submitted successfully. You can also check the order status in the IPO section of your trading account or app.

Apply early with valid UPI and PAN before 2025-11-11 to increase your chances.

The listing date of Curis Lifesciences Ltd. IPO is 2025-11-14.

An Initial Public Offering (IPO) is when a private company sells shares to the public for the first time, enabling investors to purchase these shares and gain partial ownership in the business. For instance, if a well-known tech firm wants to grow and requires additional funds, it might choose to go public through an IPO. During this process, investors can buy shares, and the company’s stock starts trading on the stock exchange on the day of the IPO listing.

Investors can apply for an IPO through their bank or brokerage account. Many trading platforms have a specific section for IPOs where users can submit their applications online.

The primary market is where shares are offered to the public for the first time via an IPO. After the IPO, shares are traded on the secondary market (stock exchange), where existing shareholders can sell to new buyers.

Investing in an IPO offers the opportunity to become an early investor in companies with high growth potential, at a price which may be lower than their post-listing market value. It provides a chance to participate in the company's growth journey from its early stages. However, IPO investments also come with inherent risks, such as market volatility and uncertainties about the company's future performance.

The price of an IPO is established through a systematic process known as "book building." In this method, investors bid within a given price range, and the final price is set based on demand and market conditions. Several factors play a crucial role in determining the IPO price, including:

Past Financial Performance: Evaluating the company's revenue, profits, and financial stability over time

Growth Potential: Assessing future prospects based on the company's business model and market opportunities

Industry Peers: Comparing valuation metrics with similar companies in the same sector

Larger Industry Picture: Analysing overall industry trends and economic conditions that could impact the company's performance

The lock-in period for IPO shares refers to a duration during which specific investors are restricted from selling their shares post-listing. This period varies based on the type of investor:

Promoters: The lock-in period for promoters ranges from 6 months to 18 months, ensuring their commitment to the company's long-term growth

Anchor Investors: Typically, anchor investors face a shorter lock-in period of 30 to 90 days, depending on regulatory norms and the specific IPO

IPOs can be volatile and may not perform as expected in the short term. Investors risk losing capital if the stock price drops after listing, especially if the company does not meet its growth projections.

Information on upcoming IPOs is often available through brokerage platforms, financial news sites, and regulatory bodies like SEBI, which publishes details on companies going public. You can also get these details under the upcoming IPO section on Bajaj Markets.

Eligibility for an IPO typically includes:

Retail Investors: Individuals who invest in smaller amounts, usually under the “retail investor” category, with certain limits

Qualified Institutional Buyers (QIBs): Entities like mutual funds, banks, and insurance companies, who invest large sums

Non-Institutional Investors (NIIs): High-net-worth individuals or entities investing above the retail threshold

Investors must have a Demat and trading account to apply, and in some cases, certain financial or residency qualifications may apply depending on local regulations.

SME (Small and Medium Enterprise) IPOs generally carry higher risk but may provide significant growth potential. Investors should research the company’s stability, financials, and sector risks, as SME stocks can be more volatile compared to large-cap companies.

View More

Invalid Mobile Number

Invalid Full Name

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore